ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD TechnologyGuruFocus · Oct 18, 2026
Natera's Signatera™ MRD Test Named to TIME's List of the Best Inventions of 2026GuruFocus · Oct 15, 2026
bioAffinity Technologies to Present New Perspectives on CyPath® Lung's Use for Cancer Risk Assessment at CHEST 2026GuruFocus · Oct 15, 2026
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal CancerGuruFocus · Oct 13, 2026
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026GuruFocus · Oct 13, 2026
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology DivisionAccesswire · Oct 13, 2026This fund aims to achieve its investment objectives by allocating capital to equity securities, including American Depositary Receipts (ADRs), issued by companies worldwide. It focuses on U.S. and international businesses whose operations, business strategies, or product offerings significantly contribute to the effort of mitigating climate change. The fund leverages ADRs to gain exposure to foreign companies, which may originate from both developed and emerging markets.